The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiaolei, Xu, Meng, Wei, Yongqiang, Huang, Fen, Zhao, Tong, Li, Xiangzhao, Feng, Ru, Ye, B Hilda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022142/
https://www.ncbi.nlm.nih.gov/pubmed/24739401
http://dx.doi.org/10.1186/1756-8722-7-34
_version_ 1782316353706786816
author Wei, Xiaolei
Xu, Meng
Wei, Yongqiang
Huang, Fen
Zhao, Tong
Li, Xiangzhao
Feng, Ru
Ye, B Hilda
author_facet Wei, Xiaolei
Xu, Meng
Wei, Yongqiang
Huang, Fen
Zhao, Tong
Li, Xiangzhao
Feng, Ru
Ye, B Hilda
author_sort Wei, Xiaolei
collection PubMed
description Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.
format Online
Article
Text
id pubmed-4022142
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40221422014-05-16 The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression Wei, Xiaolei Xu, Meng Wei, Yongqiang Huang, Fen Zhao, Tong Li, Xiangzhao Feng, Ru Ye, B Hilda J Hematol Oncol Letter to the Editor Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort. BioMed Central 2014-04-16 /pmc/articles/PMC4022142/ /pubmed/24739401 http://dx.doi.org/10.1186/1756-8722-7-34 Text en Copyright © 2014 Wei et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Wei, Xiaolei
Xu, Meng
Wei, Yongqiang
Huang, Fen
Zhao, Tong
Li, Xiangzhao
Feng, Ru
Ye, B Hilda
The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
title The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
title_full The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
title_fullStr The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
title_full_unstemmed The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
title_short The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
title_sort addition of rituximab to chop therapy alters the prognostic significance of cd44 expression
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022142/
https://www.ncbi.nlm.nih.gov/pubmed/24739401
http://dx.doi.org/10.1186/1756-8722-7-34
work_keys_str_mv AT weixiaolei theadditionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT xumeng theadditionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT weiyongqiang theadditionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT huangfen theadditionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT zhaotong theadditionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT lixiangzhao theadditionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT fengru theadditionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT yebhilda theadditionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT weixiaolei additionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT xumeng additionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT weiyongqiang additionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT huangfen additionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT zhaotong additionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT lixiangzhao additionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT fengru additionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression
AT yebhilda additionofrituximabtochoptherapyalterstheprognosticsignificanceofcd44expression

Ejemplares similares